CSPC PHARMA (01093): The Phase III clinical trial of SYS 6043 for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer has officially started at the first center in China.

CSPC PHARMA (01093) announced that a randomized, multicenter, open-label phase III clinical trial evaluating its developed SYS 6043 (B7-H3-ADC) compared to chemotherapy chosen by researchers for the treatment of platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants has officially commenced at the first center in China. The product is a targeted antibody-drug conjugate (ADC) developed by the group that specifically binds to cells expressing B7-H3 on the cell surface and internalizes into the cells. The linker-drug is a tetrapeptide linker conjugated to a topoisomerase I inhibitor, which releases small molecule toxins to kill tumor cells after protease-specific cleavage, and exerts bystander effects to nonspecifically kill surrounding tumor tissue cells. Unlike antibodies utilizing traditional wild-type crystallizable fragment (Fc), this product reduces lymphocyte uptake, lowers off-target toxicity risks, and improves treatment safety. In July 2026, the group received approval notification for the clinical trial of the drug from the China National Medical Products Administration and initiated a randomized, multicenter, open-label, positive-controlled phase III clinical trial evaluating the product compared to chemotherapy chosen by researchers for platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants. The phase III clinical trial aims to assess the clinical effectiveness and safety of the product compared to researcher-chosen chemotherapy in participants with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. Currently, subject recruitment and screening are actively ongoing.